CLASS II ONGOING Device recall · Reported 12 Aug 2026 · FDA Enforcement Report

Atellica CH Urine Albumin recalled by Siemens Healthcare Diagnostics

Siemens Healthcare Diagnostics is recalling Atellica CH Urine Albumin, distributed nationwide in the US. The recall was initiated on 6 Jul 2026 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesAll Lots within expiry/UDI: 00630414611099
Quantity recalled7018 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2890-2026
FDA event ID
99389
Recalling firm
Siemens Healthcare Diagnostics, Tarrytown, NY
Classification
Class II
Status
Ongoing
Recall initiated
6 Jul 2026
FDA classified
5 Aug 2026
Reported
12 Aug 2026
Type
Voluntary: Firm initiated
Reason category
Potency & Assay

Timeline

6 Jul 2026Recall initiated by company
5 Aug 2026Classified by FDA+30 days
12 Aug 2026Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Processing of urine albumin assay on the CI analyzers may lead to the following issues: Falsely depressed Atellica CH Urea Nitrogen (UN_c) results; Falsely depressed Atellica CH Enzymatic Hemoglobin A1c (A1c_E) results; Increased rate of reaction cuvette QC failures and Delayed results due to QC failures.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic

Where it was distributed

Worldwide distribution - US Nationwide including Puerto Rico and the countries of Australia, Austria, Bahamas, Belgium, Brazil, Canada, Chile, Curacao, St. Eus, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Ireland, Israel,¿Italy,¿Latvia, Malaysia, Netherlands, New Zealand, Norway, Portugal, Republic of Korea, Romania, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, United¿Kingdom.¿

Nationwide Puerto Rico

Questions about this recall

Why was it recalled?

Processing of urine albumin assay on the CI analyzers may lead to the following issues: Falsely depressed Atellica CH Urea Nitrogen (UN_c) results; Falsely depressed Atellica CH Enzymatic Hemoglobin A1c (A1c_E) results; Increased rate of reaction cuvette QC failures and Delayed results due to QC failures.

Which lots are affected?

All Lots within expiry/UDI: 00630414611099

Where was it sold?

Worldwide distribution - US Nationwide including Puerto Rico and the countries of Australia, Austria, Bahamas, Belgium, Brazil, Canada, Chile, Curacao, St. Eus, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Ireland, Israel,¿Italy,¿Latvia, Malaysia, Netherlands, New Zealand, Norway, Portugal, Republic of Korea, Romania, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, United¿Kingdom.¿

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Siemens Healthcare Diagnostics

All 694

Other Test Kits & Diagnostics recalls

All 2,656